BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing

Nanoscale technology developer for single-molecule analysis and imaging, BioNanomatrix announces that a $23.3 Million worth Series B equity financing round has been completed.

New and existing investors join the equity financing round, led by Domain Associates. Gund Investment is the new investor and existing investors of the company are KT Venture Group, Battelle Ventures, and Innovation Valley Partners.

R. Erik Holmlin, President and CEO of BioNanomatrix, states that the funding is secured at a critical time, as the company is progressing  towards commercializing the new genome analysis system, nanoAnalyzer. He also adds that the nanoAnalyzer 1000 System was  launched on November 2010 at the American Society of Human Genetics’ annual meeting.

The nanoAnalyzer platform is simple, affordable, and works efficiently. It reduces cost and time required for whole genome analysis. These benefits will make it feasible for wide range of applications such as research in biomedical, molecular diagnostics, and personalized medicine.

Dr. Brian K. Halak, who is joining BioNanomatrix’s Board of Directors, quotes that the company has made significant advance in developing and improving the nanoAnalyzer technology. The new financing supports the genomics company to establish its presence in West Coast, so that BioNanomatrix gains additional business opportunities.

Source: http://www.bionanomatrix.com/

Joel Scanlon

Written by

Joel Scanlon

Joel emigrated to Australia in 1995 and worked for five years in the mining industry as an exploration geotechnician, using GIS mapping and CAD software. Upon moving to the North Coast of NSW, Australia Joel worked as a graphic designer for a leading consultancy firm. After that, he ran a successful business providing web services to businesses along the eastern seaboard of Australia. During this time, he developed and launched News-Medical.Net. Joel has been working with AZoNetwork since the company was founded in 2000.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioNanomatrix. (2019, February 12). BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing. AZoNano. Retrieved on September 30, 2022 from https://www.azonano.com/news.aspx?newsID=21963.

  • MLA

    BioNanomatrix. "BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing". AZoNano. 30 September 2022. <https://www.azonano.com/news.aspx?newsID=21963>.

  • Chicago

    BioNanomatrix. "BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing". AZoNano. https://www.azonano.com/news.aspx?newsID=21963. (accessed September 30, 2022).

  • Harvard

    BioNanomatrix. 2019. BioNanomatrix to Commercialize NanoAnalyzer Platform with Series B Financing. AZoNano, viewed 30 September 2022, https://www.azonano.com/news.aspx?newsID=21963.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit